19:59 , Apr 26, 2019 |  BioCentury  |  Emerging Company Profile

ProNeurogen: Angiotensin peptides for vascular cognitive impairment

By developing native and glycosylated forms of the angiotensin-(1-7) peptide for vascular cognitive impairment, ProNeurogen hopes to plug a treatment gap that repurposed Alzheimer's disease drugs have failed to fill. There are no therapies approved...
21:19 , Feb 11, 2019 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Neurology Mouse studies identified a peptide agonist of MAS receptor that could help treat vascular dementia. The compound consists of the first six residues of angiotensin(1-7) - an endogenous peptide ligand of the MAS...
03:00 , Aug 10, 2018 |  BC Innovations  |  Targets & Mechanisms

Getting to function

A new target for sarcopenia that increases muscle function directly, in addition to adding muscle mass, could help address calls from patients and regulators to make functional recovery central to drug development in the indication....
19:28 , Jul 3, 2018 |  BC Extra  |  Company News

Management tracks: Cigna, Novocure, Voyager

Health services company Cigna Corp. (NYSE:CI) appointed Mark McClellan to its board, effective the earlier of Dec. 1 or the close of Cigna's acquisition of Express Scripts Holding Co. (NASDAQ:ESRX). McClellan is director of the...
00:27 , Oct 20, 2017 |  BC Week In Review  |  Financial News

Biophytis raises EUR10.4M in private placement

On Oct. 11, anti-aging company Biophytis S.A. (Euronext:ALBPS) raised €10.4 million ($12.3 million) in a private placement through the sale of 2 million shares at €5.25 per share. Invest Corporate Finance acted as a global...
19:44 , Apr 7, 2017 |  BC Week In Review  |  Financial News

Biophytis completes private placement and secures convertible bond financing

Age-related disease company Biophytis (Euronext:ALBPS) raised €3.7 million ($4 million) through the sale of 1.3 million shares at €2.85 in a private placement to investors including Bracknor Fund and company management on April 4. Biophytis...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Clinical News

Sarconeos: Phase I started

Biophytis began the double-blind, placebo-controlled, dose-escalation, Belgian Phase I SARA-PK trial of Sarconeos. The first part will evaluate single doses of Sarconeos in 32 elder and young healthy volunteers, and the second part will test...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Financial News

Biophytis completes debt financing

Biophytis (Euronext:ALBPS), Paris, France   Business: Musculoskeletal, Ophthalmic   Date completed: 2016-07-29   Type: Debt financing   Raised: EUR1.1 million ($1.3 million)   Shares outstanding prior: 6.2 million   Investor: Bpifrance   Note: The terms...
07:00 , Oct 5, 2015 |  BioCentury  |  Finance

Volatile, not futile

Bankers and buysiders are not ready to call the end of the biotech bull on the heels of the sector's worst quarter in more than 13 years. But they do expect volatility to persist through...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Financial News

Biophytis completes IPO

Biophytis (Euronext:ALBPS), Paris, France   Business: Musculoskeletal, Ophthalmic   Date completed: 2015-07-08   Type: IPO   Raised: EUR10 million ($11.1 million)   Shares: 1.7 million   Price: EUR6   Shares after offering: 5.4 million  ...